Cargando…
Comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus
BACKGROUND: To compare the 6-month results of two formulations of Riboflavin provided by Sina Darou, Iran, and Uznach, Switzerland, in corneal collagen cross-linking (CXL) for keratoconus patients. FINDINGS: Considering the results of the previous study about the similarity of the formulations and t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001359/ https://www.ncbi.nlm.nih.gov/pubmed/24713424 http://dx.doi.org/10.1186/2008-2231-22-37 |
_version_ | 1782313736821800960 |
---|---|
author | Hashemi, Hassan Seyedian, Mohammad Amin Miraftab, Mohammad Bahrmandy, Hooman Sabzevari, Araz Asgari, Soheila |
author_facet | Hashemi, Hassan Seyedian, Mohammad Amin Miraftab, Mohammad Bahrmandy, Hooman Sabzevari, Araz Asgari, Soheila |
author_sort | Hashemi, Hassan |
collection | PubMed |
description | BACKGROUND: To compare the 6-month results of two formulations of Riboflavin provided by Sina Darou, Iran, and Uznach, Switzerland, in corneal collagen cross-linking (CXL) for keratoconus patients. FINDINGS: Considering the results of the previous study about the similarity of the formulations and the active ingredients of the two types of Riboflavin, they were used in the CXL procedure of 60 keratoconic eyes (30 eyes in each group). After 6 months, the mean improvement of UCVA (0.239), BCVA (0.707), and MRSE (0.513) did not differ significantly between the two groups. The mean decrease in max- K (0.731), mean- K (0.264), central corneal thickness (0.759), and Q-value (0.669) did not show any significant difference between the two groups. The two groups had no significant difference in endothelial cell count decrease (0.229). The Sina Darou formulation decreased corneal hysteresis more than the Swiss formulation (P = 0.057) but there were no significant differences in the mean decrease of corneal resistance factor between the two groups (P = 0.117). CONCLUSIONS: Based on the early results, the results of visual acuity, refraction, and corneal topography using Sina Darou and Uznach formulations of Riboflavin showed that both were effective in CXL. However, considering the relatively significant difference in corneal hysteresis changes between the two groups, this study will continue to report the long-term results. |
format | Online Article Text |
id | pubmed-4001359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40013592014-04-29 Comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus Hashemi, Hassan Seyedian, Mohammad Amin Miraftab, Mohammad Bahrmandy, Hooman Sabzevari, Araz Asgari, Soheila Daru Short Communication BACKGROUND: To compare the 6-month results of two formulations of Riboflavin provided by Sina Darou, Iran, and Uznach, Switzerland, in corneal collagen cross-linking (CXL) for keratoconus patients. FINDINGS: Considering the results of the previous study about the similarity of the formulations and the active ingredients of the two types of Riboflavin, they were used in the CXL procedure of 60 keratoconic eyes (30 eyes in each group). After 6 months, the mean improvement of UCVA (0.239), BCVA (0.707), and MRSE (0.513) did not differ significantly between the two groups. The mean decrease in max- K (0.731), mean- K (0.264), central corneal thickness (0.759), and Q-value (0.669) did not show any significant difference between the two groups. The two groups had no significant difference in endothelial cell count decrease (0.229). The Sina Darou formulation decreased corneal hysteresis more than the Swiss formulation (P = 0.057) but there were no significant differences in the mean decrease of corneal resistance factor between the two groups (P = 0.117). CONCLUSIONS: Based on the early results, the results of visual acuity, refraction, and corneal topography using Sina Darou and Uznach formulations of Riboflavin showed that both were effective in CXL. However, considering the relatively significant difference in corneal hysteresis changes between the two groups, this study will continue to report the long-term results. BioMed Central 2014-04-08 /pmc/articles/PMC4001359/ /pubmed/24713424 http://dx.doi.org/10.1186/2008-2231-22-37 Text en Copyright © 2014 Hashemi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Communication Hashemi, Hassan Seyedian, Mohammad Amin Miraftab, Mohammad Bahrmandy, Hooman Sabzevari, Araz Asgari, Soheila Comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus |
title | Comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus |
title_full | Comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus |
title_fullStr | Comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus |
title_full_unstemmed | Comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus |
title_short | Comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus |
title_sort | comparison of clinical results of two pharmaceutical products of riboflavin in corneal collagen cross-linking for keratoconus |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001359/ https://www.ncbi.nlm.nih.gov/pubmed/24713424 http://dx.doi.org/10.1186/2008-2231-22-37 |
work_keys_str_mv | AT hashemihassan comparisonofclinicalresultsoftwopharmaceuticalproductsofriboflavinincornealcollagencrosslinkingforkeratoconus AT seyedianmohammadamin comparisonofclinicalresultsoftwopharmaceuticalproductsofriboflavinincornealcollagencrosslinkingforkeratoconus AT miraftabmohammad comparisonofclinicalresultsoftwopharmaceuticalproductsofriboflavinincornealcollagencrosslinkingforkeratoconus AT bahrmandyhooman comparisonofclinicalresultsoftwopharmaceuticalproductsofriboflavinincornealcollagencrosslinkingforkeratoconus AT sabzevariaraz comparisonofclinicalresultsoftwopharmaceuticalproductsofriboflavinincornealcollagencrosslinkingforkeratoconus AT asgarisoheila comparisonofclinicalresultsoftwopharmaceuticalproductsofriboflavinincornealcollagencrosslinkingforkeratoconus |